Oxford BioDynamics (GB:OBD) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oxford BioDynamics partners with King’s College London to develop EpiSwitch biomarkers aiming to improve rheumatoid arthritis (RA) treatment strategies post-Abatacept therapy. The collaboration follows the APIPPRA trial, the largest RA prevention trial, which revealed the need for better patient stratification tools. This initiative promises to enhance the identification of individuals at high risk of RA and optimize their treatment outcomes.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.